Evidence map›Paper›PMID 31754956›Full record

ArticleNeurochemical research2020

System X

M Nehser, J Dark, D Schweitzer, M Campbell, J Zwicker, D M Hitt, H Little, A Diaz-Correa, D C Holley, S A Patel and 2 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurochemical research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. The effect of Azo-dyes on glioblastoma cellsSaudi journal of biological sciences · 2023
    Article
  7. Ferroptosis Involvement in Glioblastoma Treatment.Medicina (Kaunas, Lithuania) · 2022
    Review
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

M NehserDepartment of Biomedical and Pharmaceutical Science, Center for Structural and Functional Neuroscience, Skaggs School of Pharmacy, University of Montana, Missoula, MT, 59812, USA.
J DarkDepartment of Biomedical and Pharmaceutical Science, Center for Structural and Functional Neuroscience, Skaggs School of Pharmacy, University of Montana, Missoula, MT, 59812, USA.
D SchweitzerDepartment of Biomedical and Pharmaceutical Science, Center for Structural and Functional Neuroscience, Skaggs School of Pharmacy, University of Montana, Missoula, MT, 59812, USA.
M CampbellDepartment of Biomedical and Pharmaceutical Science, Center for Structural and Functional Neuroscience, Skaggs School of Pharmacy, University of Montana, Missoula, MT, 59812, USA.
J ZwickerDeciphera Pharmaceuticals, Lawrence, KA, 66044, USA.
D M HittChemistry Department, Carroll College, Helena, MT, 56925, USA.
H LittleDepartment of Biomedical and Pharmaceutical Science, Center for Structural and Functional Neuroscience, Skaggs School of Pharmacy, University of Montana, Missoula, MT, 59812, USA.
A Diaz-CorreaDepartment of Biomedical and Pharmaceutical Science, Center for Structural and Functional Neuroscience, Skaggs School of Pharmacy, University of Montana, Missoula, MT, 59812, USA.
D C HolleyDepartment of Biomedical and Pharmaceutical Science, Center for Structural and Functional Neuroscience, Skaggs School of Pharmacy, University of Montana, Missoula, MT, 59812, USA.
S A PatelDepartment of Biomedical and Pharmaceutical Science, Center for Structural and Functional Neuroscience, Skaggs School of Pharmacy, University of Montana, Missoula, MT, 59812, USA.
C M ThompsonDepartment of Biomedical and Pharmaceutical Science, Center for Structural and Functional Neuroscience, Skaggs School of Pharmacy, University of Montana, Missoula, MT, 59812, USA.
R J BridgesDepartment of Biomedical and Pharmaceutical Science, Center for Structural and Functional Neuroscience, Skaggs School of Pharmacy, University of Montana, Missoula, MT, 59812, USA. richard.bridges@umontana.edu.ORCID http://orcid.org/0000-0002-7204-5086
University of Montana · USCarroll College · USDeciphera Pharmaceuticals (United States) · US

Funding

Surveillance genome sequencing to detect SARS-CoV-2 virus variants in MontanaP20GM103546 · NIGMS · UNIVERSITY OF MONTANA · PI BOWLER, BRUCE E · 2012 to 2021
$19.2M
Project isoPTE: isothermic post-traumatic epilepsy miRNA biomarker detectionR43NS113682 · NINDS · FYR DIAGNOSTICS, INC. · PI NORWOOD, BRAXTON, PATEL, SARJUBHAI AMRATBHAI · 2019 to 2020
$618k
Molecular Pharmacology of the System xc- Glutamate/Cystine AntiporterR15NS088899 · NINDS · UNIVERSITY OF MONTANA · PI BRIDGES, RICHARD J. · 2014 to 2014
$415k
NIGMS NIH HHS P20 GM103546NIGMS NIH HHS P20GM103546NINDS NIH HHS R15 NS088899NINDS NIH HHS R43 NS113682
6 · The paper itself

Abstract

The cystine/glutamate antiporter system X

Indexed as

Amino Acid Transport System y+Anti-Inflammatory Agents, Non-SteroidalAntiportersBinding SitesCell Line, TumorHumansMolecular Docking SimulationProtein Structure, SecondaryProtein Structure, TertiarySulfasalazineAmino Acid Transport System y+Anti-Inflammatory Agents, Non-SteroidalAntiportersSLC7A11 protein, humanSulfasalazineAminonaphthylene-sulfonateCystineGlutamateSulfasalazineSystem Xc−Transporter

Identifiers

PMID31754956
PMCPMC10688270
OpenAlexW2989754535

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.